Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).
29-05-2020 | ASCO 2020 | Conference coverage | Video
29-05-2020 | ASCO 2020 | Conference coverage | Video
Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).